Mechanism Of Action

PROVENGE® (sipuleucel-T) immunotherapy is designed to target and attack prostate cancer cells

PROVENGE is the first and only FDA-approved immunotherapy for asymptomatic or minimally symptomatic mCRPC

Targeted Mechanism of Action1
6:46
6:46
<div class=">
<div class=">
Wistia video thumbnail - DENPRO-MOA-FINAL-v009
message

The recombinant antigen used to make PROVENGE is PAP-GM-CSF. It consists of prostatic acid phosphatase (PAP), an antigen expressed in more than 95% of prostate cancers, and granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-cell activator.1